Editor’s Note: Brooke is an Ambassador and Honored Kid who just graduated from Stanford University. As Cancer Survivors Month continues on the St. Baldrick’s Blog, we’re letting her tell the story of how she got to this day in her own words.
On Thursday, September 24, 2015, my friends were finishing up their first week of junior year at Stanford. I was lying in a hospital bed, watching as my brother’s stem cells were infused into my body, replacing the bone marrow that had turned against me.
On Friday, September 25, my friends celebrated their first weekend back together at school. I had a grand mal seizure.
When I was diagnosed with acute myeloid leukemia at the end of my sophomore year of college, I knew that I was going to have a very different college experience from my peers. I had no idea how different it would be.
I had the impression that I would either die or I would live and return to my previous life. I had a high-risk form of leukemia that did not respond to my first round of chemotherapy, and at first it seemed that the death option was more likely.
But when I got into remission on a salvage round of chemotherapy and proceeded to my bone marrow transplant, I was hopeful that a return to “normal life” was possible.
Editor’s Note: Throughout the month of June, Cancer Survivors Month, we are hearing from and about those who have been diagnosed with pediatric cancers, and learning about the long-term impact and late effects of cancer treatments. The month of June also marks four years since the focus of this blog post, Brooke, was first diagnosed.
The Next Generation of Pediatric Cancer Researchers: St. Baldrick’s Foundation Fellows and Summer Fellows
It’s a lofty goal that’s right below the St. Baldrick’s logo for all to see: Conquer Childhood Cancers. And it’s a goal that takes a multi-faceted approach, a robust network of hospitals and researchers, and labs with professionals from throughout the age and experience spectrum.
As we learned recently when we interviewed Dr. Jeff Lipton, there’s real value in building a “pipeline” of researchers; and one way this pipeline grows is by funding the training of new researchers at hospitals and research organizations throughout North America.
Each year, the St. Baldrick’s Foundation picks five kids to serve as Ambassadors. In this role, they represent the thousands of kids affected by childhood cancers and remind us of the importance of supporting childhood cancer research.
Take any group of kids and they’ll all have their own way of talking, their own opinions on books, movies, and video games, their own favorite foods.
But there is one thing the St. Baldrick’s 2019 Ambassadors have in common: childhood cancers. Beyond that, they share the support of loving families and a desire to inspire others to raise money for childhood cancer research.
Our 2019 Ambassadors, from left to right: Aiden, Arianna, Sullivan, Gabby, and Brooke.
With the holiday season upon us and another year drawing to a close, it’s a great time to reflect on some of the major research accomplishments of doctors and scientists whose work on childhood cancers benefited from the support of St. Baldrick’s donors like you.
There’s much to be thankful for. All things considered, 2018 was a remarkably successful year for childhood cancer research, with much of that success spurred on by grants funded by St. Baldrick’s. Of course, none of this would have been possible without our generous donors.
Dr. Kohanbash’s cutting-edge research on ependymomas is supported by a Hero Fund in memory of Henry Cermak, who passed away in 2008 after a long, 2-year fight that included many surgeries, chemo regimens, and 93 rounds of radiation.
Honored Kid Zoe was diagnosed with acute myeloid leukemia when she was a teenager. Now, almost four years after finishing treatment and getting the news that the cancer was gone, Zoe is taking a look at what she’s learned during her cancer — and cancer-free — journey.
Honored Kid Zoe Wagner is now 19 years old and has been cancer free for four years.
The anticipation of upcoming milestones and the overall exploratory nature of the teenage years make the age of 15 a common time to be naïve – and naive I was. Life was simple and my carefree spirit allowed me to believe it would always be that way. This trusting nature also led me to ignore the severity of the disease symptoms I was having for months. As these symptoms got worse, my uncomplicated mind created uncomplicated explanations for the way I was feeling. I told myself that I was always tired because I was a teenager, and that this exhaustion was the cause of my daily headaches. I blamed my newly heavy periods on ordinary hormonal changes, bruising on being clumsy, unusually pale skin on it simply not being sunny enough out, and weight loss on, well, it happens. It wasn’t until red needle-prick like dots appeared all over my legs that I requested to go to the doctor.
With its recent commitment of $500,000 for the Target Pediatric AML initiative, the St. Baldrick’s Foundation adds another chapter to its long story of support for innovative and impactful research in childhood acute myeloid leukemia (AML).
While great progress has been made over many decades to help children survive the most common childhood cancer – acute lymphoblastic leukemia (ALL) – the same has not held true for children with AML.
St. Baldrick’s is helping change that.
A childhood cancer survivor, Brittany Ross smiles during her long-awaited wedding day to her fiance, Patrick.
When Honored Kid Brittany Ross was told that she’d be lucky to live another three weeks, she didn’t react with sadness. She didn’t bury her head under her hospital bed blankets and cry or ask, ‘Why me?’
She was mad. She was fired up. She was determined to beat childhood cancer.
“They made it seem like I had no chance,” Brittany said of her diagnosis in December 2000. “At this time, I was like, ‘Look, I’m 15 years old. I haven’t really started living my life yet.’”
And she had a come-back that any teenager would be proud of.
Acute myeloid leukemia (AML) is tough for doctors to treat. Because of that, the intense treatment needed to beat AML can be especially tough on the kids who have it. St. Baldrick’s researcher Dr. Anders Kolb wants to change that with targeted therapy. To do this, he’s getting a little help from his friends – including St. Baldrick’s.
Dr. Anders Kolb is one of St. Baldrick’s newest grantees.
Many kids in treatment for AML are getting hammered by strong treatments, like intense chemotherapy and bone marrow transplants. These therapies can save their lives, but often come with a steep cost as they grow up.
“There’s only so much we can do with the tools in our toolbox,” said Dr. Anders Kolb, who works at the Alfred I. Dupont Hospital for Children in Delaware. “We have five different hammers and they’re all really big hammers. We don’t have anything that is more subtle and more targeted.”
Not yet, at least.
What do childhood cancer researchers do when they see a problem? They band together to solve it. Read on to learn why institutions across Texas and California are joining forces and what they’re doing to help kids with cancer.
Dr. Philip Lupo is the principal investigator of the REDIAL Consortium, as well as an Associate Professor of Pediatrics at Baylor College of Medicine and Co-Director of the Epidemiology Program at Texas Children’s Cancer and Hematology Centers.
Years ago, St. Baldrick’s researcher Dr. Philip Lupo and his colleagues at Houston’s Baylor College of Medicine noticed a problem.
According to studies they read and stories Dr. Lupo heard from clinicians, kids who are Hispanic don’t do as well on treatment as other kids with acute leukemias. They are more likely to experience complications and are at higher risk of relapse than kids of other backgrounds.
But scientists don’t know exactly why that is.
Older Posts »